Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

About 60% of RA patients don’t achieve good response with biological disease-modifying anti-rheumatic drugs bDMARD treatment (including TNF inhibitors, TNFi’s). Previously, a link between TNFα and interleukin (IL)-32 was reported in RA. However, the exact mechanism linking IL-32 to response to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Damen, Michelle S. M. A., Schraa, Kiki, Tweehuysen, Lieke, den Broeder, Alfons A., Netea, Mihai G., Popa, Calin D., Joosten, Leo A. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145899/
https://www.ncbi.nlm.nih.gov/pubmed/30232372
http://dx.doi.org/10.1038/s41598-018-32485-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145899/
https://www.ncbi.nlm.nih.gov/pubmed/30232372
http://dx.doi.org/10.1038/s41598-018-32485-0

Ejemplares similares